Shackleford’s HB 1065 passes unanimously out of Senate Committee

Today, Mar. 12, State Rep. Robin Shackleford’s (D-Indianapolis) House Bill 1065 passed unanimously out the Senate Health and Provider Services Committee.  The bill proposes the creation of the Cancer Clinical Trial Participation Program, allowing independent third parties, such as patient groups, corporations, or government entities, to cover ancillary costs for patients taking part in clinical trials in Indiana.

Shackleford released the following statement on the bill’s passage:

"My family has experienced firsthand the devastating impact of cancer. My father, mother, and oldest brother all passed away from the disease in their early 50s. Among them, my mom fought the hardest, battling cancer for over five years and participating in a range of experimental treatments. Throughout this time, we repeatedly heard the urgent need for greater diversity in clinical trial participation, as well as the immense financial burdens that accompany it.

“Today, with the passage of HB 1065 out of Senate Committee and its advancement to the Senate floor, we are one step closer to securing tangible relief for the individuals and families navigating the difficult and costly process of participating in life-saving cancer clinical trials.

“For those fighting cancer, their focus should be entirely on their treatment and recovery - not the overwhelming financial strain that often accompanies the decision to join a clinical trial. By alleviating these financial burdens, this bill will allow participants to focus on what truly matters, their health and well-being, free from the added stress of unexpected costs.

“I am optimistic that, with the continued bipartisan support, we will pass this crucial legislation and make a lasting difference for those who need it most. Having lived through this experience, I can say without a doubt that the relief this bill offers is not just necessary - it’s vital."